


Advanced/Metastatic Breast Cancer 2019-2021

Advanced/Metastatic Breast Cancer 2019-2020

5th ESO-ESMO international consensus guidelines for advanced breast cancer (ABC 5)



Treatment approach to metastatic hormone receptor-positive, HER2-negative breast cancer: Endocrine therapy and targeted agents

Special Article: 5th ESO-ESMO international consensus guidelines for advanced breast cancer (ABC 5)

non- life- threatening MBC in 2019




Figure 1 Proposed therapeutic algorithm for luminal subtype non- life- threatening MBC in 2019. AI, aromatase inhibition; CDK, cyclin- dependent kinase; ER+, oestrogen receptor positive; HER2-, human epidermal growth factor 2 negative; MBC, metastatic breast cancer; NSAI, non-steroidal aromatase inhibitor; PD, progressive disease; Rx, treatment; TAM, tamoxifen. Modified by Glenn Tisman, M.D.

CDK4/6 inhibitor plus endocrine therapy for hormone receptor-positive, HER2-negative metastatic breast cancer: The new standard of care: 2021





Figure 2 Proposed therapeutic algorithm for luminal subtype MBC with non- life- threatening visceral involvement with close follow- up of the patient. CDK, cyclin- dependent kinase; ER, oestrogen receptor; ESR1, oestrogen receptor 1; MBC, metastatic breast cancer; PD, progressive disease; NSAI, non- steroidal aromatase inhibition; TAM, tamoxifen. Modified by Glenn Tisman, M.D.

ER/PR+, HER2-neg and Visceral crisis at Presentation CDK4/6 inhibition in low burden and extensive metastatic breast cancer: summary of an ESMO Open—Cancer Horizons pro and con discussion

Endocrine Therapy for Metastatic Breast Cancer Guideline ASCO Update 2021



Algorithm for endocrine treatment and targeted therapy for HR-positive, HER2-negative MBC. * Patients receiving alpelisib should have laboratory and symptom monitoring weekly for the first 4 weeks of therapy to avoid serious toxicity. CDK, cyclin-dependent kinase; HER2, human epidermal growth factor receptor 2; HR, hormone receptor; MBC, metastatic breast cancer. ** NOTE tamoxifen + a CDK4/6 inhibitor is associated with and increase in QT interval and not recommended. Modified by Glenn Tisman, M.D.

*Management of toxicity to isoform a-specific PI3K inhibitors

Chemo- and Endocrine therapy Protocols

- NCCN Protocols [Chemo- and Endocrine therapies] for regional adjuvant and neoadjuvant Rx from Cancer Therapy Advisor
- Extensive Listing of Breast Cancer Chemotherapy Protocols for [Recurrent or Metastatic Disease] from Chemotherapy Advisor April 2020 c/w NCCN 3.2020
- 2020 San Antonio Breast Cancer Symposium Abstracts
- 17th St. Gallen/Vienna 2021: A Brief Summary of the Consensus Discussion on Customizing Therapies for Women with Early Breast Cancer
- New FDA: Hematology/Oncology (Cancer) Approvals & Safety Notifications

FDA approved drugs for CaBr
Treatment Protocols
Adjuvant Protocols